U.S. health department recommends suspending the use of Johnson & Johnson's new crown vaccine

(Fighting New Coronary Pneumonia) The U.S. Health Department recommends suspending the use of Johnson & Johnson's new crown vaccine

　　China News Agency, Houston, April 13 (Reporter Zeng Jingning) The U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) said in a joint statement on the 13th that it is recommended to suspend the use of Johnson & Johnson's single-dose The new crown vaccine to review the thrombosis report data of 6 vaccinators in the United States.

　　The statement stated that the six vaccinators were women between 18 and 48 years old. They developed rare and serious blood clots 6 to 13 days after being vaccinated with the new crown vaccine developed by Johnson & Johnson.

In these cases, a type of blood clot called "Cerebral Venous Sinus Thrombosis" (CVST) was developed, which was accompanied by symptoms of low levels of platelets (thrombocytopenia).

　　The statement stated that the FDA and CDC will separately review the reported data of these cases.

The statement pointed out that "before the review is completed, out of cautious consideration, it is recommended to suspend the vaccination."

　　The statement stated that people who have received the Johnson & Johnson vaccine should contact their doctor if they experience severe headache, abdominal pain, leg pain or shortness of breath within three weeks of vaccination.

　　The statement warned doctors not to use the blood thinner Heparin, the blood thinner heparin, which is commonly used to treat blood clots, in this case. The use of this therapy may be dangerous. Please use alternative treatments.

　　Johnson & Johnson's new crown vaccine was authorized by the FDA for emergency use at the end of February this year.

Currently, most Johnson & Johnson vaccines are distributed and vaccinated in the United States.

CDC's latest statistics show that as of the 13th, US states have received a total of about 16 million doses of Johnson & Johnson vaccine, and more than 6.8 million doses have been vaccinated. Most people have no or minor side effects.

　　According to the Associated Press, US federal distribution channels will suspend the distribution of Johnson & Johnson vaccine, and US states are taking action to suspend the vaccine's vaccination.

　　Johnson & Johnson said in a statement on the 13th, "We are aware that a small number of people who have received the vaccine have extremely rare symptoms involving blood clots and low levels of platelets." The company also said that it will actively delay the vaccine in Europe. Promotion.

The company originally planned to start providing its new crown vaccine to EU countries this week.

　　It is worth mentioning that Johnson & Johnson vaccine and AstraZeneca vaccine use the same adenovirus vector technology to resist the new coronavirus.

The European Medicines Agency announced on the 7th that the rare side effects of the AstraZeneca vaccine include thrombosis and low levels of platelets.

The agency recommended the continued use of the AstraZeneca vaccine, saying its benefits outweigh the disadvantages.

And some European countries announced on the 7th that they would suspend the AstraZeneca vaccination for some people.

(Finish)